Literature DB >> 24371653

Novel TP53 gene mutation and correlation with p53 immunohistochemistry in a mixed epithelial carcinoma of the endometrium.

Andrew B Sholl1, Dara L Aisner2, Kian Behbakht3, Miriam D Post2.   

Abstract

► We examine the correlation between p53 immunohistochemistry and TP53 gene mutation status in a mixed epithelial endometrial carcinoma. ► We describe a novel R306* (c.916C > T) mutation in exon 8 of the TP53 gene. ► We propose that the distinction between Type I and Type II endometrial carcinomas may be more fluid than previously believed.

Entities:  

Keywords:  Endometrioid carcinoma; Mixed epithelial carcinoma; Serous carcinoma; TP53 gene; p53 immunohistochemistry

Year:  2012        PMID： 24371653      PMCID： PMC3862336          DOI： 10.1016/j.gynor.2012.10.005

Source DB:  PubMed          Journal:  Gynecol Oncol Case Rep        ISSN： 2211-338X


  10 in total

1.  Widely dispersed p53 mutation in respiratory epithelium. A novel mechanism for field carcinogenesis.

Authors:  W A Franklin; A F Gazdar; J Haney; I I Wistuba; F G La Rosa; T Kennedy; D M Ritchey; Y E Miller
Journal:  J Clin Invest       Date:  1997-10-15       Impact factor: 14.808

Review 2.  Molecular pathology of endometrial hyperplasia and carcinoma.

Authors:  X Matias-Guiu; L Catasus; E Bussaglia; H Lagarda; A Garcia; C Pons; J Muñoz; R Argüelles; P Machin; J Prat
Journal:  Hum Pathol       Date:  2001-06       Impact factor: 3.466

3.  IMP3 distinguishes uterine serous carcinoma from endometrial endometrioid adenocarcinoma.

Authors:  Paulette Mhawech-Fauceglia; Francois R Herrmann; Har Rai; Nana Tchabo; Shashikant Lele; Iyare Izevbaye; Kunle Odunsi; Richard T Cheney
Journal:  Am J Clin Pathol       Date:  2010-06       Impact factor: 2.493

4.  Dominant-negative mutation of p53 tumor suppressor gene in endometrial carcinoma.

Authors:  N Sakuragi; A Hirai; M Tada; H Yamada; R Yamamoto; S Fujimoto; T Moriuchi
Journal:  Gynecol Oncol       Date:  2001-12       Impact factor: 5.482

5.  Distinct sets of gene alterations in endometrial carcinoma implicate alternate modes of tumorigenesis.

Authors:  Anjila Koul; Roger Willén; Pär-Ola Bendahl; Mef Nilbert; Ake Borg
Journal:  Cancer       Date:  2002-05-01       Impact factor: 6.860

6.  p53 gene mutations are common in uterine serous carcinoma and occur early in their pathogenesis.

Authors:  H Tashiro; C Isacson; R Levine; R J Kurman; K R Cho; L Hedrick
Journal:  Am J Pathol       Date:  1997-01       Impact factor: 4.307

Review 7.  The molecular biology of endometrial cancers and the implications for pathogenesis, classification, and targeted therapies.

Authors:  Nisha Bansal; Vimala Yendluri; Robert M Wenham
Journal:  Cancer Control       Date:  2009-01       Impact factor: 3.302

8.  p53 alteration independently predicts poor outcomes in patients with endometrial cancer: a clinicopathologic study of 131 cases and literature review.

Authors:  Eun-Ju Lee; Tae-Joong Kim; Dae Shick Kim; Chel Hun Choi; Jeong-Won Lee; Je-Ho Lee; Duk-Soo Bae; Byoung-Gie Kim
Journal:  Gynecol Oncol       Date:  2009-12-14       Impact factor: 5.482

9.  p53 in endometrial cancer and its putative precursors: evidence for diverse pathways of tumorigenesis.

Authors:  M E Sherman; M E Bur; R J Kurman
Journal:  Hum Pathol       Date:  1995-11       Impact factor: 3.466

10.  Overexpression and mutation of p53 in endometrial carcinoma.

Authors:  M F Kohler; A Berchuck; A M Davidoff; P A Humphrey; R K Dodge; J D Iglehart; J T Soper; D L Clarke-Pearson; R C Bast; J R Marks
Journal:  Cancer Res       Date:  1992-03-15       Impact factor: 12.701
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.